MoonLake Immunotherapeutics downgraded by Citigroup with a new price target
$MLTX
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup downgraded MoonLake Immunotherapeutics from Buy to Neutral and set a new price target of $5.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2026 | $24.00 | Neutral → Buy | BTIG Research |
| 11/3/2025 | $30.00 | Neutral → Buy | H.C. Wainwright |
| 10/2/2025 | Buy → Neutral | H.C. Wainwright | |
| 10/1/2025 | $7.00 | Buy → Neutral | Goldman |
| 9/30/2025 | $2.00 | Outperform → Underperform | Wolfe Research |
| 9/30/2025 | $5.00 | Buy → Neutral | Citigroup |
| 9/29/2025 | $8.00 | Buy → Hold | Jefferies |
| 9/29/2025 | Buy → Neutral | BTIG Research |
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
SCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SCHEDULE 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
BTIG Research upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $24.00
H.C. Wainwright upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $30.00
H.C. Wainwright downgraded MoonLake Immunotherapeutics from Buy to Neutral
DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Markets head into the session with a familiar but powerful theme in focus: enabling technologies that quietly unlock the next wave of growth. From satellite connectivity at cruising altitude to biologics edging closer to regulatory milestones, and from AI-driven diagnostics to advanced biomaterials, today's news flow highlights companies pushing infrastructure, science, and scale forward at the same time. Connectivity Takes Flight: flyExclusive Embraces Starlink flyExclusive (NYSE:FLYX) is setting a new benchmark in private aviation after being named an authorized Starlink Aviation dealer and installer. The move brings high-speed, low-latency sat
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application (BLA) for Sonelokimab (SLK) in Hidradenitis Suppurativa (HS)FDA feedback confirms that the Company may establish substantial evidence of effectiveness (SEE), without additional clinical trials in HS, with a BLA consisting of data from its existing VELA-1, VELA-2 and MIRA trials The FDA specifically advised the Company to include the results of the MIRA trial in the submission and to submit the results of the VELA-2 trial for the marketing application to inform the safety profile of SLK, re
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cepton, Inc. (NASDAQ:CPTN) and MoonLake Immunotherapeutics (NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. MoonLake Immunotherapeutics (NASDAQ:MLTX) Class Period: March 10, 2024 to September 29, 2025Lead Plaintiff Deadline: December 15, 2025The suit alleges that MoonLake Immunotherapeutics misled investors about its sole drug candidate, sonelokima
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefitReported an interim analysis of the long-term data from the VELA-1 and VELA-2 clinical trials in adults with Hidradenitis Suppurativa (HS), as well as an interim analysis of its VELA-TEEN clinical trial in adolescent HS, demonstrating the potential and competitive benefit of SL
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facility Z
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab
SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)